8-K Announcements
6Material company update
Mar 27, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Jan 13, 2026·SEC
Rapid Micro Biosystems, Inc.(RPID)Earnings, Financials & Key Ratios
RPID•NASDAQ
$2.56
$114M mkt cap·Price updated May 7, 2026
AboutRapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.Show more
- Revenue$34M+19.7%
- EBITDA-$47M-1.8%
- Net Income-$47M-0.5%
- EPS (Diluted)-1.05+2.8%
- Gross Margin22.65%+5929.0%
- EBITDA Margin-141.1%+15.0%
- Operating Margin-141.1%+20.7%
- Net Margin-140.3%+16.1%
- ROE-86.82%-79.0%
- ROIC-69.93%-54.7%
- Debt/Equity0.72+778.3%
- Interest Coverage-43.48
RPID Key Insights
Rapid Micro Biosystems, Inc. (RPID) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 15.9%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 16 (bottom 16%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RPID Price & Volume
Rapid Micro Biosystems, Inc. (RPID) stock price & volume — 10-year historical chart
Loading chart...
RPID Growth Metrics
Rapid Micro Biosystems, Inc. (RPID) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years15.88%
3 Years25.15%
TTM16.63%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM10.71%
Return on Capital
10 Years-55.86%
5 Years-44.44%
3 Years-52.03%
Last Year-69.2%
RPID Recent Earnings
Rapid Micro Biosystems, Inc. (RPID) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Mar 12, 2026EPS
$0.28
Est $0.23
-21.7%
Revenue
$11M
Est $11M
-0.6%
Q4 2025
Nov 7, 2025EPS
$0.26
Est $0.26
+0.0%
Revenue
$8M
Est $11M
-28.3%
Q3 2025
Aug 12, 2025EPS
$0.27
Est $0.26
-3.8%
Revenue
$7M
Est $8M
-12.9%
Q2 2025
May 9, 2025EPS
$0.26
Est $0.27
+3.7%
Revenue
$7M
Est $7M
+4.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.28vs $0.23-21.7% | $11Mvs $11M-0.6% |
| Q4 2025 | Nov 7, 2025 | $0.26vs $0.26+0.0% | $8Mvs $11M-28.3% |
| Q3 2025 | Aug 12, 2025 | $0.27vs $0.26-3.8% | $7Mvs $8M-12.9% |
| Q2 2025 | May 9, 2025 | $0.26vs $0.27+3.7% | $7Mvs $7M+4.9% |
Based on last 12 quarters of dataView full earnings history →
RPID Peer Comparison
Rapid Micro Biosystems, Inc. (RPID) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IDXX | 45.45B | 572.20 | 43.75 | 10.42% | 24.63% | 70.87% | 0.67 | |
 NEOG | 2.01B | 9.25 | -1.84 | -3.2% | -68.47% | -28.64% | 0.44 | |
 BRKR | 6.66B | 43.73 | -291.53 | 2.08% | -0.34% | -0.5% | 0.81 | |
 AZTA | 855.36M | 18.57 | -15.22 | 3.55% | -29.86% | -10.69% | 0.06 | |
 BIO | 6.95B | 257.32 | 9.23 | 0.65% | 6.52% | 2.4% | 0.21 | |
 MESO | 1.91B | 14.80 | -17.62 | 191.39% | -5.94% | -17.1% | 0.21 | |
 QGEN | 6.91B | 33.53 | 16.44 | 5.65% | 20.33% | 11.85% | 0.44 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 |
Compare RPID vs Peers
Rapid Micro Biosystems, Inc. (RPID) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RPID Income Statement
Rapid Micro Biosystems, Inc. (RPID) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 16.51M | 16.08M | 23.23M | 17.13M | 22.52M | 28.05M | 33.59M | 30.52M |
| Revenue Growth % | - | -2.63% | 44.5% | -26.25% | 31.44% | 24.57% | 19.74% | 16.63% |
| Cost of Goods Sold | 16.75M | 24.15M | 30.97M | 25.67M | 28M | 28.16M | 25.98M | 24.92M |
| COGS % of Revenue | 101.42% | 150.2% | 133.32% | 149.85% | 124.36% | 100.39% | 77.35% | - |
| Gross Profit | -234K▲ 0% | -8.07M▼ 3349.1% | -7.74M▲ 4.1% | -8.54M▼ 10.3% | -5.49M▲ 35.8% | -109K▲ 98.0% | 7.61M▲ 7079.8% | 5.61M▲ 0% |
| Gross Margin % | -1.42% | -50.2% | -33.32% | -49.85% | -24.36% | -0.39% | 22.65% | 18.37% |
| Gross Profit Growth % | - | -3349.15% | 4.09% | -10.32% | 35.77% | 98.01% | 7079.82% | - |
| Operating Expenses | 18.4M | 22.47M | 39.49M | 54.68M | 51.08M | 49.81M | 55M | 51.02M |
| OpEx % of Revenue | 111.43% | 139.76% | 169.99% | 319.14% | 226.82% | 177.57% | 163.75% | - |
| Selling, General & Admin | 12.97M | 15.94M | 29.71M | 41.81M | 38.26M | 35.21M | 34.84M | 33.98M |
| SG&A % of Revenue | 78.55% | 99.14% | 127.88% | 244.05% | 169.89% | 125.53% | 103.72% | - |
| Research & Development | 5.43M | 6.53M | 9.78M | 12.87M | 12.82M | 14.6M | 13.6M | 13.79M |
| R&D % of Revenue | 32.88% | 40.62% | 42.1% | 75.09% | 56.93% | 52.04% | 40.5% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 6.56M | 2M |
| Operating Income | -18.63M▲ 0% | -30.54M▼ 63.9% | -47.23M▼ 54.7% | -63.22M▼ 33.8% | -56.56M▲ 10.5% | -49.92M▲ 11.7% | -47.39M▲ 5.1% | -45.41M▲ 0% |
| Operating Margin % | -112.85% | -189.96% | -203.31% | -368.99% | -251.18% | -177.96% | -141.1% | -148.77% |
| Operating Income Growth % | - | -63.89% | -54.66% | -33.85% | 10.53% | 11.75% | 5.06% | - |
| EBITDA | -17.13M | -29.04M | -45.7M | -60.38M | -53.46M | -46.56M | -47.39M | -42.08M |
| EBITDA Margin % | -103.77% | -180.63% | -196.72% | -352.43% | -237.39% | -165.97% | -141.1% | -137.86% |
| EBITDA Growth % | - | -69.49% | -57.38% | -32.12% | 11.47% | 12.91% | -1.79% | 13.81% |
| D&A (Non-Cash Add-back) | 1.5M | 1.5M | 1.53M | 2.84M | 3.1M | 3.36M | 0 | 3.33M |
| EBIT | -18.37M | -33.5M | -47.23M | -63.22M | -56.56M | -49.92M | -47.39M | -44.82M |
| Net Interest Income | -2.38M | -3.45M | -2.65M | 1.78M | 4.21M | 3.16M | 419K | 1.35M |
| Interest Income | 0 | 0 | 0 | 1.78M | 4.21M | 3.16M | 1.51M | 1.76M |
| Interest Expense | 2.38M | 3.45M | 2.65M | 0 | 0 | 0 | 1.09M | 417K |
| Other Income/Expense | -2.11M | -6.4M | -26.2M | 1.84M | 4.13M | 3.05M | 309K | 1.14M |
| Pretax Income | -20.74M▲ 0% | -36.94M▼ 78.1% | -73.43M▼ 98.8% | -61.38M▲ 16.4% | -52.44M▲ 14.6% | -46.87M▲ 10.6% | -47.08M▼ 0.5% | -44.27M▲ 0% |
| Pretax Margin % | -125.63% | -229.79% | -316.09% | -358.27% | -232.85% | -167.08% | -140.18% | -145.05% |
| Income Tax | 427K | 134K | 91K | -576K | 31K | 22K | 40K | 17K |
| Effective Tax Rate % | -2.06% | -0.36% | -0.12% | 0.94% | -0.06% | -0.05% | -0.08% | -0.04% |
| Net Income | -21.17M▲ 0% | -37.08M▼ 75.1% | -73.52M▼ 98.3% | -60.81M▲ 17.3% | -52.47M▲ 13.7% | -46.89M▲ 10.6% | -47.12M▼ 0.5% | -44.29M▲ 0% |
| Net Margin % | -128.22% | -230.63% | -316.48% | -354.91% | -232.99% | -167.16% | -140.3% | -145.11% |
| Net Income Growth % | - | -75.14% | -98.3% | 17.3% | 13.71% | 10.63% | -0.5% | 8.48% |
| Net Income (Continuing) | -21.17M | -37.08M | -73.52M | -60.81M | -52.47M | -46.89M | -47.12M | -44.29M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.53▲ 0% | -1.17▼ 120.8% | -1.88▼ 60.7% | -1.43▲ 23.9% | -1.22▲ 14.7% | -1.08▲ 11.5% | -1.05▲ 2.8% | -0.99▲ 0% |
| EPS Growth % | - | -120.75% | -60.68% | 23.94% | 14.69% | 11.48% | 2.78% | 10.71% |
| EPS (Basic) | -0.53 | -1.17 | -1.88 | -1.43 | -1.22 | -1.08 | -1.05 | - |
| Diluted Shares Outstanding | 39.66M | 38.67M | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M | 44.53M |
| Basic Shares Outstanding | 39.66M | 38.67M | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M | 44.53M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
RPID Balance Sheet
Rapid Micro Biosystems, Inc. (RPID) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 23.61M | 62.15M | 218.12M | 138.58M | 120.42M | 80.92M | 61.17M | 69.95M |
| Cash & Short-Term Investments | 12.46M | 45.08M | 193.5M | 108.65M | 92.05M | 50.73M | 38.3M | 41.25M |
| Cash Only | 12.46M | 30.08M | 178.39M | 27.06M | 24.29M | 16.91M | 20.03M | 18.95M |
| Short-Term Investments | 0 | 15M | 15.11M | 81.58M | 67.77M | 33.82M | 18.27M | 22.3M |
| Accounts Receivable | 4.92M | 5.78M | 5.63M | 5.48M | 5.58M | 7.53M | 3.13M | 5.43M |
| Days Sales Outstanding | 108.74 | 131.32 | 88.48 | 116.77 | 90.49 | 97.92 | 34.06 | 70.49 |
| Inventory | 5.75M | 8.96M | 15.67M | 21.19M | 19.96M | 20.2M | 17.59M | 21.07M |
| Days Inventory Outstanding | 125.37 | 135.51 | 184.67 | 301.22 | 260.17 | 261.83 | 247.18 | 302.32 |
| Other Current Assets | 336K | 546K | 440K | 705K | 577K | 843K | 2.15M | 2.21M |
| Total Non-Current Assets | 8.08M | 7.85M | 23.05M | 52.07M | 23.04M | 17.25M | 13.68M | 14.46M |
| Property, Plant & Equipment | 7.59M | 7.05M | 11.3M | 20.88M | 19.07M | 16.36M | 13.08M | 13.96M |
| Fixed Asset Turnover | 2.17x | 2.28x | 2.06x | 0.82x | 1.18x | 1.72x | 2.57x | 2.01x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 152K | 0 | 9.97M | 29.79M | 2.91M | 365K | 0 | 284K |
| Other Non-Current Assets | 332K | 795K | 1.77M | 1.4M | 1.05M | 531K | 603K | 2.49M |
| Total Assets | 31.69M▲ 0% | 70M▲ 120.9% | 241.17M▲ 244.5% | 190.65M▼ 20.9% | 143.45M▼ 24.8% | 98.17M▼ 31.6% | 74.85M▼ 23.8% | 84.41M▲ 0% |
| Asset Turnover | 0.52x | 0.23x | 0.10x | 0.09x | 0.16x | 0.29x | 0.45x | 0.36x |
| Asset Growth % | - | 120.89% | 244.54% | -20.95% | -24.76% | -31.57% | -23.75% | -120.38% |
| Total Current Liabilities | 10.53M | 15.54M | 18.17M | 19.05M | 18.99M | 17.57M | 18.49M | 16.55M |
| Accounts Payable | 3.21M | 4.47M | 3.94M | 5.43M | 1.97M | 2.54M | 4.14M | 3.59M |
| Days Payables Outstanding | 69.99 | 67.53 | 46.48 | 77.17 | 25.72 | 32.86 | 58.15 | 44.3 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 1.21M | 1.3M | 0 |
| Deferred Revenue (Current) | 1.88M | 4.42M | 3.31M | 4.71M | 5.97M | 6.6M | 4.73M | 23.9M |
| Other Current Liabilities | 2.58M | 2.88M | 4.04M | 3.74M | 4.95M | 4.62M | 8.32M | 6.36M |
| Current Ratio | 2.24x | 4.00x | 12.01x | 7.27x | 6.34x | 4.61x | 3.31x | 3.31x |
| Quick Ratio | 1.70x | 3.42x | 11.14x | 6.16x | 5.29x | 3.46x | 2.36x | 2.36x |
| Cash Conversion Cycle | 164.12 | 199.29 | 226.68 | 340.82 | 324.95 | 326.88 | 223.08 | 328.52 |
| Total Non-Current Liabilities | 21.89M | 29.63M | 2.02M | 7.43M | 6.48M | 5.25M | 23.16M | 23.53M |
| Long-Term Debt | 17.81M | 24.81M | 0 | 0 | 0 | 0 | 22.58M | 18.83M |
| Capital Lease Obligations | 0 | 0 | 0 | 7.2M | 6.21M | 4.95M | 0 | 17.92M |
| Deferred Tax Liabilities | -683K | -705K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4.08M | 4.82M | 2.02M | 229K | 263K | 298K | 583K | 1.62M |
| Total Liabilities | 32.41M | 45.18M | 20.19M | 26.48M | 25.46M | 22.82M | 41.65M | 40.08M |
| Total Debt | 17.81M | 24.81M | 0 | 7.97M | 7.35M | 6.17M | 23.87M | 24.11M |
| Net Debt | 5.35M | -5.27M | -178.39M | -19.1M | -16.94M | -10.74M | 3.84M | 5.16M |
| Debt / Equity | - | 1.00x | - | 0.05x | 0.06x | 0.08x | 0.72x | 0.72x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.57x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -0.12x |
| Interest Coverage | -7.85x | -8.86x | -17.82x | - | - | - | -43.48x | -107.47x |
| Total Equity | -725K▲ 0% | 24.82M▲ 3523.4% | 220.98M▲ 790.3% | 164.17M▼ 25.7% | 117.99M▼ 28.1% | 75.35M▼ 36.1% | 33.21M▼ 55.9% | 44.33M▲ 0% |
| Equity Growth % | - | 3523.45% | 790.33% | -25.71% | -28.13% | -36.14% | -55.93% | -164.11% |
| Book Value per Share | -0.02 | 0.64 | 5.33 | 3.87 | 2.74 | 1.73 | 0.74 | 1.00 |
| Total Shareholders' Equity | -725K | 24.82M | 220.98M | 164.17M | 117.99M | 75.35M | 33.21M | 44.33M |
| Common Stock | 4K | 6K | 415K | 421K | 424K | 430K | 445K | 442K |
| Retained Earnings | -204.51M | -241.59M | -315.11M | -375.92M | -428.38M | -475.27M | -522.4M | -509.9M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 1K | -16K | -1.11M | -101K | 39K | 11K | 12K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RPID Cash Flow Statement
Rapid Micro Biosystems, Inc. (RPID) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -21.15M | -31M | -54.96M | -58.55M | -45.08M | -44.15M | -31.06M | -31.06M |
| Operating CF Margin % | -128.07% | -192.8% | -236.59% | -341.72% | -200.19% | -157.4% | -92.48% | - |
| Operating CF Growth % | - | -46.57% | -77.33% | -6.52% | 23% | 2.06% | 29.65% | 36.17% |
| Net Income | -21.17M | -37.08M | -73.52M | -60.81M | -52.47M | -46.89M | -47.12M | -44.29M |
| Depreciation & Amortization | 1.46M | 1.51M | 1.53M | 2.84M | 3.1M | 3.36M | 3.25M | 3.33M |
| Stock-Based Compensation | 473K | 533K | 1.84M | 4.02M | 4.75M | 3.87M | 4.03M | 4.09M |
| Deferred Taxes | -249K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 449K | 5.14M | 23.19M | 728K | -1.02M | 271K | 8.78M | 2.04M |
| Working Capital Changes | -2.11M | -1.1M | -8M | -5.33M | 555K | -4.77M | 0 | -2.9M |
| Change in Receivables | -511K | -1.36M | -17K | -364K | -163K | -1.99M | 4.39M | -1.69M |
| Change in Inventory | -3.92M | -3.37M | -6.77M | -5.84M | 1.19M | -335K | 1.47M | -580K |
| Change in Payables | 1.03M | 978K | -524K | 1.48M | -3.46M | 562K | 1.6M | 1.26M |
| Cash from Investing | -1.7M | -15.67M | -13.29M | -93.47M | 42.15M | 36.66M | 14.33M | 15.3M |
| Capital Expenditures | -1.7M | -690K | -3.22M | -6.74M | -1.84M | -1.36M | -850K | -856K |
| CapEx % of Revenue | 10.27% | 4.29% | 13.85% | 39.34% | 8.19% | 4.87% | 2.53% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 20K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 14.87M | 64.23M | 216.75M | 693K | 149K | 203K | 19.77M | 19.32M |
| Debt Issued (Net) | 0 | 16.5M | -26.17M | -33K | -37K | -35K | 0 | 19.97M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 0 | 0 | 238K | 0 | 261K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 162K | 0 |
| Other Financing | 0 | -2.2M | -940K | 726K | 186K | 0 | 19.77M | -911K |
| Net Change in Cash | -7.97M▲ 0% | 17.57M▲ 320.4% | 148.49M▲ 745.2% | -151.32M▼ 201.9% | -2.78M▲ 98.2% | -7.37M▼ 165.3% | 3.04M▲ 141.2% | -3.02M▲ 0% |
| Free Cash Flow | -22.84M▲ 0% | -31.69M▼ 38.7% | -58.18M▼ 83.6% | -65.29M▼ 12.2% | -46.93M▲ 28.1% | -45.52M▲ 3.0% | -31.91M▲ 29.9% | -38.58M▲ 0% |
| FCF Margin % | -138.34% | -197.09% | -250.43% | -381.06% | -208.38% | -162.27% | -95.01% | -126.4% |
| FCF Growth % | - | -38.72% | -83.62% | -12.21% | 28.12% | 3% | 29.89% | 15.07% |
| FCF per Share | -0.58 | -0.82 | -1.40 | -1.54 | -1.09 | -1.04 | -0.71 | -0.71 |
| FCF Conversion (FCF/Net Income) | 1.00x | 0.84x | 0.75x | 0.96x | 0.86x | 0.94x | 0.66x | 0.87x |
| Interest Paid | 0 | 1.98M | 2.59M | 42K | 38K | 0 | 0 | 189K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RPID Key Ratios
Rapid Micro Biosystems, Inc. (RPID) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -307.77% | -59.82% | -31.58% | -37.19% | -48.5% | -86.82% | -73.91% |
| Return on Invested Capital (ROIC) | -189.51% | -114.01% | -50.53% | -34.47% | -45.2% | -69.93% | -69.93% |
| Gross Margin | -50.2% | -33.32% | -49.85% | -24.36% | -0.39% | 22.65% | 18.37% |
| Net Margin | -230.63% | -316.48% | -354.91% | -232.99% | -167.16% | -140.3% | -145.11% |
| Debt / Equity | 1.00x | - | 0.05x | 0.06x | 0.08x | 0.72x | 0.72x |
| Interest Coverage | -8.86x | -17.82x | - | - | - | -43.48x | -107.47x |
| FCF Conversion | 0.84x | 0.75x | 0.96x | 0.86x | 0.94x | 0.66x | 0.87x |
| Revenue Growth | -2.63% | 44.5% | -26.25% | 31.44% | 24.57% | 19.74% | 16.63% |
RPID SEC Filings & Documents
Rapid Micro Biosystems, Inc. (RPID) SEC filings — annual & quarterly reports (10-K, 10-Q)
RPID Frequently Asked Questions
Rapid Micro Biosystems, Inc. (RPID) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rapid Micro Biosystems, Inc. (RPID) reported $30.5M in revenue for fiscal year 2025. This represents a 85% increase from $16.5M in 2019.
Rapid Micro Biosystems, Inc. (RPID) grew revenue by 19.7% over the past year. This is strong growth.
Rapid Micro Biosystems, Inc. (RPID) reported a net loss of $44.3M for fiscal year 2025.
Dividend & Returns
Rapid Micro Biosystems, Inc. (RPID) has a return on equity (ROE) of -86.8%. Negative ROE indicates the company is unprofitable.
Rapid Micro Biosystems, Inc. (RPID) had negative free cash flow of $38.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More RPID
Rapid Micro Biosystems, Inc. (RPID) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates